The FTC’s USAP and Welsh Carson matter is the flagship public example for healthcare rollup diligence: the buyer has to test whether the platform’s value comes from operational improvement or from market power regulators may challenge.
By Noah Green CPA CFE
This article is for general diligence education. It is not legal advice, investment advice, tax advice, or a conclusion about any specific party. The FTC alleged misconduct. Welsh Carson settled administratively without an admission of liability. The FTC announced an agreement in principle with USAP in April 2026, subject to execution and court approval. Verify current posture before publication. All 2025 and 2026 dates and posture facts should be confirmed against the primary sources listed at the end of this article before any publication or distribution.
The Short Version
The FTC alleged that U.S. Anesthesia Partners and Welsh Carson used a rollup strategy to consolidate Texas anesthesia practices and raise prices. The public posture is specific:
- Complaint filed Sept. 21, 2023.
- Welsh Carson dismissed from the federal case May 13, 2024.
- FTC final order with Welsh Carson approved May 20, 2025.
- FTC announced an agreement in principle with USAP April 23, 2026, subject to execution and court approval.
For buyers, this is not just an antitrust story. It is a diligence story. If the acquisition thesis depends on payer-rate lift after consolidation, the buyer needs market-share, contract, and board-record testing before signing, not after. The USAP matter illustrates that regulators are willing to examine the rollup thesis itself, not only individual transactions, and that sponsor-level conduct can produce separate administrative consequences even when the federal case against the sponsor is dismissed.
For the broader framework, see the private equity healthcare rollup diligence guide and SPP’s FTC Franchise Rule guide.
Public Posture
The FTC’s case targeted a Texas anesthesia platform rollup. The agency alleged serial acquisitions, price-setting arrangements, and market-allocation agreements created a dominant anesthesia provider and raised prices for patients and payers.
The posture is mixed and must be stated carefully. The district court in the Southern District of Texas dismissed Welsh Carson from the federal case in May 2024. The FTC later approved a final administrative order with Welsh Carson in May 2025. The FTC’s April 2026 release announced a path to restore competition in Texas anesthesia markets through an agreement in principle with USAP, but the FTC release notes that the USAP relief was still subject to execution and court approval as of that date.
What that means for a practitioner reading this article: the Welsh Carson administrative order is final and public. The USAP matter is not yet a final stipulated order as of the April 2026 release. Anyone relying on this article for a specific transaction should pull the current docket and the FTC press page to confirm whether a final USAP order has been entered and what its public terms are.
The FTC, DOJ, and HHS also issued a cross-government healthcare consolidation request for information in March 2024, signaling that the USAP matter is not an isolated enforcement event but part of a coordinated federal focus on healthcare market concentration. That context matters for any buyer evaluating a physician-practice rollup today.
The Mechanism Regulators Alleged
The alleged mechanism was not a single bad invoice or a billing-code error. It was the rollup thesis itself, applied to a specialty with high facility dependence and limited payer alternatives.
The FTC alleged that the strategy worked in several steps. First, USAP acquired anesthesia practices in targeted Texas markets, building a dominant provider position around specific hospitals and ambulatory surgery centers. Second, the platform used contracting arrangements and alleged competitor agreements to affect pricing and market structure. Third, consolidation was converted into payer-rate leverage because payers had limited ability to contract around a dominant provider at key facilities.
The alleged market-allocation element is particularly important for diligence purposes. The FTC’s theory was not only that USAP grew large, but that the growth was accompanied by arrangements that reduced competitive alternatives. A buyer evaluating any physician-practice platform should understand the difference between organic scale, which is generally lawful, and arrangements that allocate markets or coordinate pricing with competitors, which are the conduct the FTC targeted here.
The mechanism also illustrates why board materials matter. If a board deck describes the acquisition rationale in terms of reducing competitive alternatives, controlling facility access, or achieving pricing power over payers, those documents become relevant to an antitrust analysis. The FTC’s ability to examine internal strategy documents is one reason why diligence teams should read board materials before signing, not only after a problem surfaces.
The Welsh Carson administrative order adds a sponsor-level dimension. The order limits Welsh Carson’s involvement with USAP and requires advance notice for specified future anesthesia and hospital-based physician practice deals. That means the consequences of the alleged rollup strategy extended to the sponsor’s future investment activity, not only to the portco’s operations. A buyer acquiring a platform from a sponsor subject to a consent order needs to understand whether the order restricts the seller’s ability to cooperate in transition, provide representations, or participate in future add-on activity.
Warning Signs for Buyers
The USAP matter produces a specific set of warning signs that a buyer or investor should test before signing or before wiring funds. These are not generic compliance flags. They are the specific document and data patterns that the public record suggests were relevant to the FTC’s theory.
Acquisition map concentration. If the platform’s acquisition history shows a pattern of buying every meaningful competitor in a defined metro or facility network, that pattern is the starting point for an antitrust market-share analysis. A buyer should map acquisitions by geography, facility affiliation, and payer contract before relying on the platform’s own market-share representations.
Rate-lift narrative without operational explanation. Deal decks that celebrate payer-rate increases without explaining the operational improvement that justified those increases are a red flag. Rate lift that follows consolidation, rather than quality improvement or cost reduction, is the pattern the FTC alleged. A buyer should ask the seller to explain each material rate increase by contract, date, and the operational or contractual basis for the increase.
Facility exclusivity or practical lock-in. Anesthesia and other hospital-based specialties often operate under facility contracts that give one group exclusive or preferred access to a hospital or surgery center. Those contracts are not inherently unlawful, but they can create the market structure the FTC found problematic when combined with a dominant market position. A buyer should review all facility contracts for exclusivity terms, renewal rights, and termination triggers.
Physician noncompetes and affiliation restrictions. Noncompete agreements that prevent physicians from practicing at competing facilities, or affiliation agreements that restrict physicians from joining other groups, can contribute to the market-power analysis. A buyer should inventory all physician-level noncompetes and affiliation restrictions and assess whether they are enforceable under applicable state law and whether they create the kind of market-entry barrier the FTC examined.
Side letters or coordination documents. Any document that references competitors, territories, pricing, or market allocation is a serious diligence flag. The FTC’s market-allocation theory depended on evidence of coordination beyond ordinary competitive behavior. A buyer should require a representation that no such documents exist and should conduct targeted document review to test that representation.
Payer-rate assumptions built on limited alternatives. If the financial model assumes payers will accept higher rates because they have no practical alternative at key facilities, the model is pricing in market power. A buyer should stress-test the rate assumptions against a scenario in which a new entrant or payer-directed alternative becomes available.
Sponsor-level consent order restrictions. If the seller’s sponsor is subject to a consent order that restricts future acquisitions or requires advance notice to regulators, a buyer needs to understand whether those restrictions affect the transaction structure, the seller’s ability to provide representations and warranties, or the platform’s ability to pursue add-on acquisitions post-close.
The same buyer discipline appears in SPP’s Burgerim case study: a buyer should test the business mechanism before relying on the sales narrative.
Diligence Tests Before Signing or Before The Wire
The following tests are specific to the antitrust and market-power risks illustrated by the USAP matter. They are not a complete diligence checklist. They are the tests that the public record suggests are most relevant to this enforcement pattern.
Build a specialty-by-specialty market share map by metro, facility, and payer. Do not rely on the seller’s market-share representations. Pull CMS provider data, state licensure records, and facility contract lists to construct an independent map. Identify the top five facilities by revenue and determine what share of anesthesia services at each facility the platform controls.
Compare pre-rollup and post-rollup payer rates by contract and effective date. For each major payer contract, identify the rate in effect before the platform’s first acquisition in that market and the rate in effect today. If rates increased materially after consolidation, ask the seller to explain the basis for each increase. Document the explanation and assess whether it is operationally credible.
Review all affiliation agreements, noncompetes, MSAs, facility contracts, and side letters. Request a complete schedule of every agreement that restricts physician mobility, facility access, or competitive entry. Review each agreement for terms that could support a market-allocation or exclusivity theory. Flag any agreement that references competitors, territories, or pricing.
Read board materials for rollup rationale, rate strategy, competitor references, and exit assumptions. Board materials are the most direct evidence of the strategic intent behind the rollup. A buyer should request board minutes, board decks, and investment committee materials for the full period of the platform’s acquisition activity. Look for language that describes the acquisition strategy in terms of market control, competitive elimination, or payer leverage.
Interview antitrust counsel before signing if the platform’s value depends on market concentration. This is not a standard legal-review step. It is a specific antitrust-risk assessment that should happen before the buyer commits to a price. Antitrust counsel should review the market-share map, the payer-rate bridge, and the board materials and provide a written assessment of the enforcement risk.
Require a schedule of pending CIDs, regulator contacts, competitor disputes, payor disputes, and consent-order restrictions. A civil investigative demand from the FTC or DOJ is a material disclosure item. A buyer should require the seller to represent that no CID, investigative subpoena, or regulator inquiry is pending or has been received in the past three years. If the seller cannot make that representation, the buyer needs to understand the scope of the inquiry before signing.
Test the payer-rate model against a competitive-entry scenario. If a new anesthesia group entered the platform’s top three markets, what would happen to payer rates? If the answer is that rates would fall materially, the model is pricing in market power that may not be durable. A buyer should require the seller to run that scenario and should assess whether the purchase price is supportable without the market-power premium.
Check the seller’s sponsor for consent-order restrictions. Pull the Welsh Carson final order and any other public consent orders applicable to the seller’s sponsor. Identify any restrictions on future acquisitions, notice requirements, or cooperation obligations. Assess whether those restrictions affect the transaction or the platform’s post-close acquisition strategy.
Conduct a whistleblower and litigation docket check. Search PACER and state court dockets for qui tam complaints, competitor litigation, and physician disputes. A qui tam complaint under seal will not appear in a docket search, but a pattern of physician departures, competitor complaints, or payer disputes may signal underlying conduct risk.
Reconcile the acquisition history against the market-share map. For each acquisition, confirm the date, the acquired group’s pre-acquisition market share, and the platform’s post-acquisition market share in the relevant market. If the platform’s market share crossed a material threshold after a specific acquisition, that acquisition is the most likely focus of any future antitrust review.
How to Read the Primary Source Documents
The FTC press releases and the district court order are the primary public sources for this matter. A practitioner reading those documents for diligence purposes should focus on specific elements.
The FTC complaint. The complaint describes the alleged mechanism in detail, including the specific markets, the acquisition sequence, and the alleged coordination conduct. A buyer evaluating a similar platform should read the complaint’s market-definition section to understand how the FTC defines the relevant market for anesthesia services. The complaint’s description of facility-level market power is directly applicable to any hospital-based specialty rollup.
The S.D. Tex. motion-to-dismiss order. The district court’s order dismissing Welsh Carson from the federal case addresses the legal theory of sponsor liability for portco conduct. A buyer’s counsel should read this order to understand the current state of the law on when a PE sponsor’s involvement in a portco’s strategy creates direct antitrust exposure. The order does not mean the FTC’s theory was wrong; it means the court found the complaint insufficient to sustain the federal case against Welsh Carson at the pleading stage. The FTC’s subsequent administrative order with Welsh Carson shows that the agency pursued the matter through a different channel.
The Welsh Carson final order. The administrative order is the most directly actionable document for a buyer evaluating a platform with a PE sponsor. The order’s restrictions on Welsh Carson’s future anesthesia investments and its notice requirements for specified deals are the kind of sponsor-level restrictions that a buyer must identify and assess before signing. A buyer should ask whether the seller’s sponsor is subject to any similar order and should pull the public order text to confirm the scope of the restrictions.
The FTC April 2026 release. The release announces an agreement in principle with USAP but does not disclose the terms of the relief. A buyer should check the FTC’s docket for any subsequent final order and should not assume that the agreement in principle reflects the final terms of any USAP relief.
By the Numbers
| Data Point | Public Source Fact | Buyer Diligence Meaning |
|---|---|---|
| Complaint date | FTC complaint filed Sept. 21, 2023 | Rollup conduct can become a live enforcement issue years after acquisitions close. The platform’s acquisition history is a diligence document, not only a growth narrative. |
| Welsh Carson federal posture | Welsh Carson dismissed from federal case May 13, 2024 | Case posture is not the same for every defendant. A federal dismissal does not resolve administrative exposure. Buyers must track both channels. |
| Welsh Carson administrative posture | FTC final order approved May 20, 2025 | Settlement terms can restrict future sponsor conduct even without an admission of liability. A buyer must review any consent order applicable to the seller’s sponsor before signing. |
| USAP posture as of April 2026 | FTC announced agreement in principle April 23, 2026, subject to execution and court approval | Publication and transaction diligence must verify whether a final stipulated order exists and what its public terms are. Do not rely on the press release alone. |
| Sponsor-level relief type | Welsh Carson order limits involvement with USAP and requires notice for specified future anesthesia and hospital-based physician practice deals | Buyers must diligence sponsor-level restrictions, not only portco financials. A restricted sponsor may affect transition support, representations, and post-close add-on strategy. |
| Cross-government enforcement signal | FTC, DOJ, and HHS issued a joint healthcare consolidation RFI in March 2024 | The USAP matter is part of a coordinated federal focus on healthcare market concentration. Any physician-practice rollup buyer should assess the current enforcement environment, not only the specific USAP facts. |
| Relevant statute and theory | FTC Act Section 5, Clayton Act Section 7, Sherman Act-style monopolization and restraint theories through FTC enforcement | The FTC has multiple enforcement channels for healthcare consolidation. A buyer’s antitrust counsel should assess exposure under each applicable theory, not only the theory pursued in the federal complaint. |
Source footer: Figures and posture are drawn from the public primary sources listed below. Verify current posture before publication or reliance.
Buyer / Investor Takeaway
The USAP matter produces three specific lessons for a buyer or investor evaluating a physician-practice rollup.
First, the rollup thesis is the diligence question. If the platform’s value depends on payer-rate lift that followed consolidation, the buyer must understand whether that rate lift reflects lawful scale or market power that regulators may challenge. The FTC’s theory was that the rate lift in the USAP matter reflected market power, not operational improvement. A buyer who accepts the seller’s rate-lift narrative without testing it against the market-share map and the payer-contract history is accepting the seller’s legal conclusion, not conducting independent diligence.
Second, sponsor-level restrictions are transaction-level facts. The Welsh Carson final order restricts the sponsor’s future conduct and requires advance notice for specified deals. A buyer acquiring a platform from a sponsor subject to a similar order needs to understand whether the order affects the transaction structure, the seller’s ability to provide representations and warranties, or the platform’s post-close acquisition strategy. Sponsor-level consent orders are not disclosed in the portco’s financial statements. A buyer must check the public enforcement record for the seller’s sponsor independently.
Third, the enforcement environment is active. The FTC, DOJ, and HHS issued a joint healthcare consolidation RFI in March 2024. The USAP matter was filed in September 2023 and produced a final Welsh Carson order in May 2025 and a USAP agreement in principle in April 2026. That timeline shows that healthcare rollup enforcement is not a theoretical risk. It is an active enforcement priority with a multi-year litigation and administrative track. A buyer pricing a physician-practice rollup today should build the enforcement risk into the valuation, not treat it as a tail risk that can be addressed post-close.
For investors evaluating a fund that holds physician-practice platforms, the USAP matter is also a portfolio-level signal. A fund with multiple anesthesia, emergency medicine, or hospitalist platforms in concentrated markets should be able to explain the market-share position of each platform and the basis for payer-rate assumptions. If the fund cannot provide that explanation, the investor should treat the gap as a diligence finding, not a disclosure oversight.
SPP Bottom Line
The USAP matter is a practical warning for rollup buyers: do not treat antitrust risk as a late legal checklist item. Diligence the market map, payer-rate bridge, and board-record theory first. If the economics depend on reduced competitive alternatives, the enforcement risk is part of the valuation.
The Welsh Carson administrative order adds a specific procedural lesson. A sponsor can face separate administrative consequences even when the federal case against it is dismissed. A buyer must check both the federal docket and the FTC’s administrative enforcement record before concluding that a sponsor is clear of enforcement exposure.
The USAP agreement in principle, announced in April 2026 and still subject to execution and court approval as of that date, means the matter is not fully resolved. A buyer or investor relying on this article should pull the current FTC docket to confirm the current posture before signing or wiring.
The broader enforcement environment, including the March 2024 cross-government RFI and the pattern of physician-staffing and hospital-based specialty enforcement actions, confirms that the USAP matter is not an outlier. It is the most prominent public example of a regulatory theory that applies to any specialty rollup where consolidation produces payer-rate lift without a clear operational explanation.